Trial Profile
Compassionate Use Treatment Protocol I4V-MC-JAGA: Treatment of Conditions Expected to Benefit From JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, and Severe Juvenile Dermatomyositis
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary)
- Indications Autoimmune disorders; Dermatomyositis; Skin disorders
- Focus Expanded access; Therapeutic Use
- Acronyms JAGAT
- Sponsors Eli Lilly and Company
- 09 Nov 2021 Results (n=10) assessing disease flares in CANDLE/PRAAS with dose reductions of baricitinib, presented at the ACR Convergence 2021
- 09 Nov 2021 Results (n=4) assessing Dosing and Patient-Reported Outcomes in Refractory Juvenile Dermatomyositis presented at the ACR Convergence 2021
- 14 Nov 2017 Results of pooled data from two trial (NCT02974595 and NCT01724580) assessing pharmacokinetics, pharmacodynamics and oral dosing regimen of baricitinib in patients with rare interferonopathies, were published in the Clinical Pharmacology and Therapeutics.